相似文献
1
Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
Heart. 2005 Feb;91(2):131-2. doi: 10.1136/hrt.2004.041756.
2
Can metabolic manipulation reverse myocardial dysfunction?
Eur Heart J. 2001 Dec;22(23):2138-9. doi: 10.1053/euhj.2001.2699.
3
Metabolic therapy for heart failure.
Eur Heart J. 2004 Oct;25(20):1765-8. doi: 10.1016/j.ehj.2004.08.019.
4
The heart metabolism: pathophysiological aspects in ischaemia and heart failure.
Curr Pharm Des. 2009;15(8):827-35. doi: 10.2174/138161209787582101.
5
[Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Presse Med. 1998 Dec 12;27(39):2100-4.
6
Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
Indian Heart J. 2017 May-Jun;69(3):393-401. doi: 10.1016/j.ihj.2017.04.001. Epub 2017 Apr 29.
7
Metabolic modulation as a target for heart failure treatment: current perspective.
Indian Heart J. 2007 Jul-Aug;59(4):370-4.
8
Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Am J Cardiol. 1998 Sep 3;82(5A):14K-17K. doi: 10.1016/s0002-9149(98)00532-3.
9
Metabolic treatment of myocardial ischaemia.
Eur Heart J. 1999 Aug;20(16):1144-5. doi: 10.1053/euhj.1999.1719.
10
Trimetazidine in the myocardial cell mechanisms of cytoprotection.
Rom J Intern Med. 1998 Jul-Dec;36(3-4):137-44.
本文引用的文献
1
Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.
Heart. 2005 Feb;91(2):161-5. doi: 10.1136/hrt.2003.031310.
2
Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure.
J Cardiovasc Pharmacol. 2004 Jul;44(1):101-8. doi: 10.1097/00005344-200407000-00014.
3
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Eur Heart J. 2004 Apr;25(8):634-41. doi: 10.1016/j.ehj.2004.02.018.
4
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
JAMA. 2004 Jan 21;291(3):309-16. doi: 10.1001/jama.291.3.309.
5
Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.
Cardiovasc Diabetol. 2003 Nov 28;2:16. doi: 10.1186/1475-2840-2-16.
6
The heart failure revascularisation trial (HEART): rationale, design and methodology.
Eur J Heart Fail. 2003 Jun;5(3):295-303. doi: 10.1016/s1388-9842(03)00056-4.
7
Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
Circulation. 2001 May 22;103(20):2441-6. doi: 10.1161/01.cir.103.20.2441.
8
Is it time for a randomized trial of surgical treatment of ischemic heart failure?
J Am Coll Cardiol. 2001 Apr;37(5):1210-3. doi: 10.1016/s0735-1097(01)01123-8.
9
The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Circ Res. 2000 Mar 17;86(5):580-8. doi: 10.1161/01.res.86.5.580.
10
Fatty acid oxidation enzyme gene expression is downregulated in the failing heart.
Circulation. 1996 Dec 1;94(11):2837-42. doi: 10.1161/01.cir.94.11.2837.
Zotero 插件